Torisel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Implemented as a Drug Use Investigation by Central Registration System
- Patients treated with Torisel (patients with metastatic and/or radically unresectable
or advanced renal cell carcinoma).
- Patients not administered Torisel.
- Patients with a history of severe hypersensitivity to temsirolimus, sirolimus
derivative, or any of their components and/or derivatives.
Type of Study:
Observational Model: Case-Only, Time Perspective: Prospective
The incidence of adverse events
Outcome Time Frame:
Pfizer CT.gov Call Center
Japan: Pharmaceuticals and Medical Devices Agency
- Renal Cell Carcinoma
- Regulatory Post Marketing Commitment Plan
- Carcinoma, Renal Cell